Steely Comments on Effects of Revised FFCRA Regulations

Foley & Lardner LLP partner Brian Tomkins is featured across legal press for his recent arrival to the firm.

Foley & Lardner LLP partner Nathan Beaver discussed the ongoing deliberations at the U.S. Food and Drug Administration over a popular class of drugs in the PharmaVoice article, "GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?"

Foley & Lardner LLP partner Brian Wheeler commented in the Pitchbook article, "GP-led secondaries to end 2024 with new record," assessing the prospects for dealmaking in the space heading into 2025.